What is HC Wainwright’s Estimate for Humacyte Q2 Earnings?

Humacyte, Inc. (NASDAQ:HUMA) – Equities researchers at HC Wainwright issued their Q2 2025 EPS estimates for shares of Humacyte in a research report issued on Wednesday, May 14th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings of ($0.14) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.27) per share.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.09. The firm had revenue of $0.52 million during the quarter, compared to analyst estimates of $0.46 million.

Other equities analysts have also issued reports about the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research note on Tuesday. Benchmark reduced their target price on shares of Humacyte from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $11.71.

Humacyte Stock Up 18.5%

Shares of HUMA stock opened at $2.24 on Friday. Humacyte has a 12-month low of $1.15 and a 12-month high of $9.97. The firm has a market capitalization of $347.47 million, a price-to-earnings ratio of -1.67 and a beta of 1.64. The firm has a fifty day moving average of $1.83 and a 200-day moving average of $3.49.

Insider Buying and Selling

In other Humacyte news, CFO Dale A. Sander purchased 20,000 shares of the business’s stock in a transaction on Thursday, April 10th. The shares were purchased at an average cost of $1.53 per share, with a total value of $30,600.00. Following the transaction, the chief financial officer now directly owns 40,600 shares of the company’s stock, valued at $62,118. This represents a 97.09% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kathleen Sebelius purchased 50,000 shares of the business’s stock in a transaction on Tuesday, April 8th. The shares were acquired at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the transaction, the director now directly owns 91,207 shares in the company, valued at approximately $120,393.24. This represents a 121.34% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 83,993 shares of company stock valued at $118,224. Company insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Humacyte

Several institutional investors and hedge funds have recently added to or reduced their stakes in HUMA. Brookstone Capital Management bought a new stake in Humacyte during the 4th quarter worth about $56,000. ARS Investment Partners LLC lifted its position in Humacyte by 17.8% during the 4th quarter. ARS Investment Partners LLC now owns 99,419 shares of the company’s stock worth $502,000 after buying an additional 15,000 shares in the last quarter. ACT Wealth Management LLC bought a new stake in shares of Humacyte in the 4th quarter valued at about $57,000. SG Americas Securities LLC raised its holdings in shares of Humacyte by 22.0% in the 4th quarter. SG Americas Securities LLC now owns 39,143 shares of the company’s stock valued at $198,000 after purchasing an additional 7,069 shares during the period. Finally, Wealth Effects LLC raised its holdings in shares of Humacyte by 89.1% in the 4th quarter. Wealth Effects LLC now owns 121,400 shares of the company’s stock valued at $613,000 after purchasing an additional 57,200 shares during the period. 44.71% of the stock is owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.